[go: up one dir, main page]

MY187167A - Medical treatments based on anamorelin - Google Patents

Medical treatments based on anamorelin

Info

Publication number
MY187167A
MY187167A MYPI2017700714A MYPI2017700714A MY187167A MY 187167 A MY187167 A MY 187167A MY PI2017700714 A MYPI2017700714 A MY PI2017700714A MY PI2017700714 A MYPI2017700714 A MY PI2017700714A MY 187167 A MY187167 A MY 187167A
Authority
MY
Malaysia
Prior art keywords
anamorelin
therapeutically effective
medical treatments
treatments based
patient
Prior art date
Application number
MYPI2017700714A
Inventor
William Mann
John Friend
William Polvino
Suzan Allen
Ming Lu
Elizabeth Duus
Ruben Giorgino
Enrico Baroni
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY187167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MY187167A publication Critical patent/MY187167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods of treating cancer related conditions using anamorelin are described. The principal embodiment relates to the unique condition of patients defining this condition by treating cachexia in a human cancer patient, comprising administering to said patient a therapeutically effective amount of anamorelin for a therapeutically effective period of time, and observed surprising ability of anamorelin to increase lean body mass in this population.
MYPI2017700714A 2014-09-04 2015-08-28 Medical treatments based on anamorelin MY187167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (1)

Publication Number Publication Date
MY187167A true MY187167A (en) 2021-09-07

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017700714A MY187167A (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Country Status (44)

Country Link
US (5) US9675600B2 (en)
EP (2) EP3590338A3 (en)
JP (3) JP6356907B2 (en)
KR (3) KR102307275B1 (en)
CN (5) CN107205389A (en)
AP (1) AP2017009772A0 (en)
AR (1) AR103118A1 (en)
AU (1) AU2015312231B2 (en)
BR (1) BR112017003552A2 (en)
CA (1) CA2959158A1 (en)
CL (1) CL2017000494A1 (en)
CO (1) CO2017003263A2 (en)
CR (1) CR20170121A (en)
CY (1) CY1122746T1 (en)
DK (1) DK3188599T3 (en)
DO (1) DOP2017000055A (en)
EA (1) EA035578B1 (en)
EC (1) ECSP17019893A (en)
ES (1) ES2761777T3 (en)
GE (1) GEP20186939B (en)
HR (1) HRP20192345T1 (en)
HU (1) HUE046894T2 (en)
IL (1) IL250692B (en)
JO (1) JO3541B1 (en)
LT (1) LT3188599T (en)
MA (1) MA40607B1 (en)
MD (1) MD4710C1 (en)
ME (1) ME03597B (en)
MX (1) MX361741B (en)
MY (1) MY187167A (en)
NI (1) NI201700024A (en)
PE (1) PE20171109A1 (en)
PH (1) PH12017500392B1 (en)
PL (1) PL3188599T3 (en)
PT (1) PT3188599T (en)
RS (1) RS59751B1 (en)
SG (1) SG11201701567UA (en)
SI (1) SI3188599T1 (en)
SV (1) SV2017005400A (en)
TN (1) TN2017000040A1 (en)
TW (1) TWI639429B (en)
UA (1) UA120765C2 (en)
UY (1) UY36286A (en)
WO (1) WO2016036598A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
HUE046894T2 (en) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Medical treatments based on anamorelin
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
AU2020276213A1 (en) 2019-05-10 2021-10-28 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
WO2021038519A1 (en) 2019-08-30 2021-03-04 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
TW202128165A (en) * 2019-10-24 2021-08-01 日商東麗股份有限公司 Therapeutic or prophylactic agent for cachexia
WO2023042158A1 (en) * 2021-09-17 2023-03-23 Helsinn Healthcare Sa Methods of determining and providing clinically meaningful improvements on patient reported outcomes in anorexia / cachexia patients
WO2025004650A1 (en) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 Agent and composition for reducing fatigue in middle-aged and older persons

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993021A (en) 1999-06-16 1999-08-12 THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
ECSP993020A (en) 1999-06-16 1999-08-12 COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
JP2007523048A (en) * 2003-08-06 2007-08-16 ガストロテック・ファルマ・アクティーゼルスカブ Use of secretagogues
CN1863550A (en) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
WO2005097261A1 (en) 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
EP1768976B1 (en) * 2004-06-29 2017-04-26 Helsinn Healthcare S.A. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (en) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. Treatment method of cell proliferative disease using growth hormone secretagogue
TWI429436B (en) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc Methods of treating or preventing emesis using growth hormone secretagogues
JO3353B1 (en) 2012-04-20 2019-03-13 Ono Pharmaceutical Co Isolated solid form of anamorelin monohydrochloride with low molar ratio of chloride : anamolerin and low content of residual organic solvent
WO2013175805A1 (en) * 2012-05-25 2013-11-28 Raqualia Pharma Inc. Ghrelin receptor agonists for the treatment of achlorhydria
HUE046894T2 (en) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Medical treatments based on anamorelin

Also Published As

Publication number Publication date
JO3541B1 (en) 2020-07-05
AU2015312231A1 (en) 2017-03-23
CN113577073A (en) 2021-11-02
MX361741B (en) 2018-12-14
MA40607B1 (en) 2019-11-29
MX2017002825A (en) 2017-09-28
SV2017005400A (en) 2017-04-20
UA120765C2 (en) 2020-02-10
ES2761777T3 (en) 2020-05-21
CO2017003263A2 (en) 2017-07-28
JP2018154655A (en) 2018-10-04
HRP20192345T1 (en) 2020-03-20
NZ729673A (en) 2023-09-29
GEP20186939B (en) 2018-12-25
US11723902B2 (en) 2023-08-15
US10894041B2 (en) 2021-01-19
IL250692A0 (en) 2017-04-30
PH12017500392A1 (en) 2017-07-17
JP2017526695A (en) 2017-09-14
DOP2017000055A (en) 2017-08-15
JP7044918B2 (en) 2022-03-30
LT3188599T (en) 2019-12-10
US10278964B2 (en) 2019-05-07
KR20170047372A (en) 2017-05-04
TWI639429B (en) 2018-11-01
KR102234319B1 (en) 2021-04-01
EP3590338A3 (en) 2020-03-18
NI201700024A (en) 2017-07-18
AU2015312231B2 (en) 2017-10-19
EP3188599B1 (en) 2019-10-02
US20160067236A1 (en) 2016-03-10
US9675600B2 (en) 2017-06-13
IL250692B (en) 2019-05-30
JP2021080281A (en) 2021-05-27
JP6923486B2 (en) 2021-08-18
WO2016036598A1 (en) 2016-03-10
PL3188599T3 (en) 2020-06-01
EP3188599A1 (en) 2017-07-12
CN107375285A (en) 2017-11-24
CN113577074A (en) 2021-11-02
CN107205389A (en) 2017-09-26
UY36286A (en) 2016-02-29
TN2017000040A1 (en) 2018-07-04
RS59751B1 (en) 2020-02-28
CA2959158A1 (en) 2016-03-10
MD4710C1 (en) 2021-04-30
JP6356907B2 (en) 2018-07-11
CR20170121A (en) 2017-07-17
US20170296526A1 (en) 2017-10-19
ECSP17019893A (en) 2017-05-31
ME03597B (en) 2020-07-20
EP3590338A2 (en) 2020-01-08
KR102307275B1 (en) 2021-09-30
KR101881264B1 (en) 2018-07-23
PT3188599T (en) 2020-01-15
KR20180085047A (en) 2018-07-25
TW201613587A (en) 2016-04-16
MD4710B1 (en) 2020-09-30
AR103118A1 (en) 2017-04-19
CL2017000494A1 (en) 2017-09-15
HUE046894T2 (en) 2020-04-28
CY1122746T1 (en) 2021-03-12
BR112017003552A2 (en) 2017-12-05
US20240024303A1 (en) 2024-01-25
US20190175574A1 (en) 2019-06-13
EP3188599A4 (en) 2017-10-11
PH12017500392B1 (en) 2018-08-31
SI3188599T1 (en) 2020-02-28
KR20210035923A (en) 2021-04-01
EA035578B1 (en) 2020-07-09
SG11201701567UA (en) 2017-03-30
CN109172575A (en) 2019-01-11
MD20170025A2 (en) 2017-07-31
AP2017009772A0 (en) 2017-02-28
PE20171109A1 (en) 2017-08-07
US20210093627A1 (en) 2021-04-01
DK3188599T3 (en) 2019-11-25
EA201790352A1 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
PH12017500392A1 (en) Medical treatments based on anamorelin
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
MX2021004828A (en) Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy.
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
MX2022011334A (en) Treatment of fabry disease in ert-naãve and ert-experienced patients.
MX2016005532A (en) Methods for using nitric oxide in a plasma state to treat medical conditions and diseases.
MX370953B (en) USE OF LEVOCETIRIZINE and MONTELUKAST IN THE TREATMENT OF AUTOIMMUNE DISORDERS.
MX2017006938A (en) Combination therapy for treatment of cancer.
MX2015011905A (en) Use of levocetirizine and montelukast in the treatment of vasculitis.
MX2018010223A (en) Combination therapy for treatment of ovarian cancer.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA202193276A1 (en) METHODS FOR THE TREATMENT OF CHOLANGIOCARCINOMA
MX2019003751A (en) Therapeutic protein.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020008881A (en) Methods of treatment of cancer comprising chk1 inhibitors.
MY205171A (en) Methods of treatment of hypertriglyceridemia
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.
BR112017002449A2 (en) treatment of symptoms associated with androgen deprivation therapy
MX2017013668A (en) Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer.
UA113183C2 (en) METHOD OF ADIATION TREATMENT
HK1233917A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
EA201692163A1 (en) MEDICINE FOR THE TREATMENT OF PATIENTS WITH TINNITUS
UA89857U (en) Device for treating mesial occlusion